Investor Relations
The Leader in Brachytherapy
Isoray advances innovative radiotherapeutic technologies that focus on the patient.
Latest Results
Isoray Reschedules Fourth Quarter and Fiscal Year End 2021 Financial Results Conference Call to September 22, 2021 Due to Conference Provider Technical Issues
Conference Call Rescheduled for Wednesday, September 22 at 10:00 a.m. ET/7:00 a.m. PT RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options...
Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2021 Financial Results
Record Full Year Revenue Fiscal Fourth Quarter Revenue Increased 19% Year-Over-Year RICHLAND, WASHINGTON – September 21, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options...
Isoray To Announce Fourth Quarter and Fiscal Year End 2021 Financial Results on September 21, 2021
Conference Call is Tuesday, September 21 at 4:30 p.m. ET/1:30 p.m. PT RICHLAND, WASHINGTON – September 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in brachytherapy powering expanding treatment options throughout the body,...
Isoray Announces Second Quarter Fiscal 2021 Financial Results
Revenue Increased 7% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 92% Year-Over-Year RICHLAND, WASHINGTON – February 9, 2021 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Isoray Announces First Quarter Fiscal 2021 Financial Results
Revenue Increased 3% Year-Over-Year Non-Prostate Brachytherapy Revenue Increased 104% Year-Over-Year RICHLAND, WASHINGTON – November 10, 2020 – Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding...
Investor Resources
Research Analyst Coverage
Northland Capital Markets
Tim Chiang
Lake Street Capital Markets, LLC
Frank Takkinen
Oppenheimer & Co.
Suraj Kalia, CFA
Dawson James Securities Inc.
Jason Kolbert
Ascendiant Capital Markets
Edward Woo
Do you have questions?
Investor Relations:
Mark Levin
Global IR Group
mark@globalirgroup.com